When responding to outbreaks of viral disease, public health officials are often challenged...
- Vaccine development: the need for speed
- Lack of CMO availability threatens cell and gene therapy development
- Novaliq’s NovaTears+Omega-3 represents the first-in-class omega-3-containing eye drop for evaporative dry eye
- Surprisingly good Phase II results for ibudilast in progressive MS
- Tenapanor likely to makes waves in IBS-C space
April’s top news stories
Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma
Cabometyx (cabozantinib) is used for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).
Keytruda (pembrolizumab) for the Treatment of Metastatic Melanoma
Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy initially indicated for the treatment of unresectable or metastatic melanoma.
B&W Tek NanoRam Handheld Raman Spectrometer
The NanoRam is a state-of-the-art handheld Ramen instrument for non-destructive identification and verification of incoming raw materials such as active pharmaceutical ingredients (API), excipients, and intermediates.
Paradigm Shift Regarding API and Formulation Components
This whitepaper will provide an introduction to high-purity carbohydrates often used for applications such as stabilisation, modulation, and cryopreservation, comparing the old paradigm that formulation components are inactive ingredients with limited functionality with the new paradigm, which suggests these components play a significant role in therapeutic stability, quality, potency, immunogenicity, and bioavailability.
Jardiance (empagliflozin) for the Treatment of Type 2 Diabetes
Jardiance (empagliflozin) is a once daily tablet indicated for the treatment of adult patients with type 2 diabetes. The drug is developed and marketed by Boehringer Ingelheim Pharmaceuticals in collaboration with Eli Lilly and Company.
Adcetris® for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma
Adcetris® (brentuximab vedotin) is a treatment for relapsed or refractory (r/r) Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL) that was developed by Seattle Genetics and Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical.
Blincyto® (blinatumomab) for the Treatment of B-cell Precursor Acute Lymphoblastic Leukaemia
Blincyto® (blinatumomab) is a monoclonal antibody indicated as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.